GLP-1 & Weight-Loss Clinical Trials Recruiting Now (2026)
62 GLP-1 and weight-loss clinical trials are actively recruiting across 45 US states as of July 14, 2026. Taking part can give you access to investigational treatment and study-provided care; many trials also reimburse your time and travel — the amount, if any, is set by each study and shown when you contact the team.
Are GLP-1 clinical trials paid?
Some are. Clinical trials cannot pay you to improve your health results, but most reimburse out-of-pocket costs — time, travel, parking, and sometimes a stipend per visit. The amount varies widely by study and site, and it is disclosed by the study team, not advertised as a headline figure. We link every listing straight to its ClinicalTrials.gov record so you can confirm eligibility, compensation, and contact details from the source.
This is not medical advice or a recruitment service — we do not run these studies or receive anything for listing them. Discuss any trial with your own clinician before enrolling.
Find a trial by state
All recruiting GLP-1 & weight-loss trials
- Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Phase 3 · ~80 participants · NCT05819853
Studied intervention: Semaglutide Injectable Product (Wegovy and/or Ozempic)
- Feasibility of Semaglutide in Advanced Lung Disease
Phase 1, Phase 2 · ~8 participants · NCT05746039
Studied intervention: Semaglutide Pen Injector
- Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Phase 2 · ~126 participants · NCT06582875
Studied intervention: Tirzepatide
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Phase 2 · ~1481 participants · NCT06143956
Studied intervention: Tirzepatide
Arizona, California, Connecticut, Florida, Hawaii, Idaho +16 more
- Impact GLP-1 Agonists Following Bariatric
Phase 4 · ~150 participants · NCT06132477
Studied intervention: GLP-1 receptor agonist
- Tirzepatide in Obesity-Driven Endometrial Cancer
EARLY_Phase 1 · ~20 participants · NCT07065552
Studied intervention: Tirzepatide
- Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
Phase 1 · ~20 participants · NCT07095517
Studied intervention: Tirzepatide
- Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Interventional · ~50 participants · NCT06967389
Studied intervention: Ozempic®
- Weight Loss in Adults Using Semaglutide (Real-world Study)
Interventional · ~35000 participants · NCT07627074
Studied intervention: Semaglutide
- Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss
EARLY_Phase 1 · ~42 participants · NCT06734273
Studied intervention: Mounjaro
- Impact of Semaglutide on Tobacco Use and Related Health Behaviors
Phase 4 · ~40 participants · NCT06986993
Studied intervention: Semaglutide
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Phase 4 · ~200 participants · NCT06864026
Studied intervention: Tirzepatide
Arizona, California, Florida, Georgia, Illinois, Indiana +11 more
- Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Phase 2 · ~66 participants · NCT05912621
Studied intervention: Tirzepatide
- Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
EARLY_Phase 1 · ~30 participants · NCT06759701
Studied intervention: Tirzepatide
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
Phase 4 · ~40 participants · NCT07218445
Studied intervention: Tirzepatide
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Phase 2 · ~465 participants · NCT06717698
Studied intervention: Semaglutide
California, Colorado, Florida, Illinois, Indiana, Michigan +5 more
- Tirzepatide for Alcohol Use Disorder
Phase 2 · ~42 participants · NCT06994338
Studied intervention: Tirzepatide
- A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Phase 2 · ~230 participants · NCT07639021
Studied intervention: Semaglutide, Semaglutide placebo
Alabama, California, Florida, Illinois, Indiana, Kentucky +11 more
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
Phase 2 · ~63 participants · NCT05933499
Studied intervention: Tirzepatide
- A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Phase 1 · ~80 participants · NCT07184086
Studied intervention: CagriSema (Cagrilintide B + semaglutide I)
- Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
Phase 2 · ~20 participants · NCT07228741
Studied intervention: Tirzepatide
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Phase 3 · ~800 participants · NCT07153471
Studied intervention: Orforglipron
Arizona, California, Colorado, Connecticut, Georgia, Illinois +11 more
- GLP-1R Actions on Muscle and the Skeleton
Phase 4 · ~50 participants · NCT07154719
Studied intervention: Tirzepatide
- Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Phase 4 · ~30 participants · NCT07257484
Studied intervention: Tirzepatide
- Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Phase 1 · ~62 participants · NCT07673900
Studied intervention: semaglutide SC
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Phase 3 · ~125 participants · NCT06672549
Studied intervention: Orforglipron
California, Connecticut, Georgia, Illinois, Louisiana, Mississippi +7 more
- Tirzepatide in PWS, HO and GNSO
Phase 4 · ~36 participants · NCT06901245
Studied intervention: Tirzepatide
- Sit Less, Interact and Move More (SLIMM) 2 Study
Phase 2 · ~156 participants · NCT05173714
Studied intervention: Semaglutide
- Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
Phase 1 · ~40 participants · NCT06575738
Studied intervention: Injectable semaglutide
- Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Interventional · ~20 participants · NCT05419726
Studied intervention: Semaglutide Injectable Product (not provided by the study)
- Semaglutide for Post-Smoking Cessation Weight Management
Phase 2 · ~197 participants · NCT06173778
Studied intervention: semaglutide 2.4mg
- Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Phase 3 · ~1200 participants · NCT07284979
Studied intervention: Semaglutide
Arizona, Arkansas, California, Connecticut, Florida, Georgia +13 more
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Interventional · ~300 participants · NCT07702461
Studied intervention: Glucagon-Like Peptide-1 Agonist (GLP-1)
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
N/A · ~40 participants · NCT07091500
Studied intervention: Semaglutide
- Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Phase 2 · ~20 participants · NCT06811324
Studied intervention: Tirzepatide
- Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
EARLY_Phase 1 · ~8 participants · NCT06934642
Studied intervention: Tirzepatide
- A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Phase 1 · ~60 participants · NCT07465965
Studied intervention: Semaglutide Nasal Spray, Semaglutide Injection
- Incretin Microdosing for Cardiometabolic Health in People With HIV
Phase 2 · ~30 participants · NCT07325500
Studied intervention: Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly, Dose escalation to 2 mg semaglutide weekly then no semaglutide
- Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
Interventional · ~20 participants · NCT07169136
Studied intervention: GLP-1 Receptor Agonists
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Interventional · ~100 participants · NCT07207148
Studied intervention: GLP-1
- A Study of a Weight Loss Intervention in People With Endometrial Cancer
EARLY_Phase 1 · ~36 participants · NCT06751589
Studied intervention: Tirzepatide
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Phase 4 · ~100 participants · NCT07213466
Studied intervention: semaglutide
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Phase 3 · ~2500 participants · NCT07564414
Studied intervention: Semaglutide
Alabama, Arizona, Arkansas, California, Colorado, Florida +24 more
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Phase 3 · ~1000 participants · NCT07202884
Studied intervention: Orforglipron
Alabama, Arizona, California, Colorado, Florida, Georgia +5 more
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Phase 4 · ~200 participants · NCT06857942
Studied intervention: Tirzepatide
Arizona, California, Florida, Georgia, Indiana, Kentucky +16 more
- Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Phase 1 · ~75 participants · NCT07225816
Studied intervention: Liraglutide, Oral Semaglutide, Semaglutide
- Pharmacogenetics of Response to GLP1R Agonists
Phase 1 · ~600 participants · NCT05071898
Studied intervention: Semaglutide Pen Injector [Ozempic]
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Phase 3 · ~150 participants · NCT06672939
Studied intervention: Orforglipron
California, Connecticut, Georgia, Illinois, Louisiana, Mississippi +6 more
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Phase 3 · ~300 participants · NCT06439277
Studied intervention: Tirzepatide
California, Delaware, Idaho, Illinois, Indiana, New York +2 more
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Phase 3 · ~290 participants · NCT06937099
Studied intervention: Tirzepatide
Alabama, California, Florida, Idaho, Illinois, Indiana +16 more
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Phase 3 · ~460 participants · NCT07253285
Studied intervention: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
California, Florida, Georgia, Idaho, Indiana, Kansas +13 more
- Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Phase 2 · ~48 participants · NCT06517212
Studied intervention: Tirzepatide
- Mechanisms of Semaglutide Therapy in Heart Failure Patients
Phase 1, Phase 2 · ~10 participants · NCT06541509
Studied intervention: Semaglutide
- Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Phase 2 · ~54 participants · NCT06411210
Studied intervention: Semaglutide Pen Injector
- Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Phase 3 · ~200 participants · NCT06499857
Studied intervention: Semaglutide
- Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Phase 2 · ~105 participants · NCT06847399
Studied intervention: Tirzepatide
- Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
Phase 2 · ~120 participants · NCT06903923
Studied intervention: GLP-1 receptor agonist
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Phase 3 · ~586 participants · NCT07035093
Studied intervention: Retatrutide
Arizona, California, Colorado, Florida, Kansas, Louisiana +8 more
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Phase 3 · ~350 participants · NCT06937086
Studied intervention: Tirzepatide
Alabama, California, Florida, Idaho, Illinois, Indiana +17 more
- TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Phase 2 · ~100 participants · NCT06802081
Studied intervention: Tirzepatide
- 2024 Tirzepatide-Bariatric Surgery
Phase 4 · ~50 participants · NCT06721507
Studied intervention: tirzepatide
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Phase 2 · ~200 participants · NCT07446998
Studied intervention: Semaglutide (Wegovy) weekly injection
Arizona, Florida, Georgia, Louisiana, Maryland, Mississippi +4 more
Source: ClinicalTrials.gov (US National Library of Medicine), public-domain data, snapshot July 14, 2026. Trial status, eligibility, and compensation change — always confirm on the linked ClinicalTrials.gov record.